Azithromycin is a 15-membered macrolide antibiotic. In vitro tests have shown that azithromycin has antibacterial effects on a variety of common clinical pathogens, including: Gram-positive aerobic bacteria, Staphylococcus aureus, Streptococcus pyogenes (group A beta; hemolytic streptococci), pneumonia (streptococci), a-hemolytic streptococci (grass-green streptococci) and other streptococci, diphtheria (rod-shaped) bacilli. This product shows cross-resistance to erythromycin-resistant Gram-positive bacteria, including fecal streptococci (enterococci) and various methicillin-resistant Staphylococcus strains.

Animal experiments have shown that this product can reduce the increase of serum AST and ALT in the animal acute liver injury model caused by TAA (thioacetamide) and CC14 (carbon tetrachloride), and inhibit the accumulation of triglycerides caused by chronic liver injury model; it can promote liver glycogen synthesis, inhibit the increase of cholesterol, and help the recovery of serum albumin/globulin ratio.

Animal experiments have shown that this product can reduce the increase of serum AST and ALT in the animal acute liver injury model caused by TAA (thioacetamide) and CC14 (carbon tetrachloride), and inhibit the accumulation of triglycerides caused by chronic liver injury model; it can promote liver glycogen synthesis, inhibit the increase of cholesterol, and help the recovery of serum albumin/globulin ratio.

This product has the effect of inhibiting platelet aggregation, thromboxane A2 production, atherosclerotic lipid plaque formation and immune complexes, and can dilate peripheral and coronary blood vessels.

Proteolytic enzyme. It can dissolve blood clots, inhibit thrombosis, and improve microcirculation.